Skip to main content

Spineway Expansion in Asia

Written by Customer Service on . Posted in Public Companies.

Press release                                                                           Ecully, February 11th, 2021 – 6:30 p.m.
Continued expansion in Asia :First implantation of the Mont Blanc 3D+ in ThailandSignature of an Exclusive Distribution Agreement in MalaysiaSpineway, specialized in the treatment of severe disorders of the spine, announces the first surgery in Thailand with Mont Blanc 3D+ instrumentation as well as the signature of an exclusive distribution agreement for the marketing of its products in Malaysia.This operation was successfully performed on February 4th, 2021 by Dr Chatchawarl Sarntipiphat, orthopedic surgeon at Srinagarind University Hospital in Khon Kaen Province, Thailand, on an 11-year-old patient with idiopathic scoliosis.Doctor Sarntipiphat specifies the context of this operation : “This type of scoliosis requires a surgical correction because the permanent deviation of the spine can cause a deformation of the vertebral bodies, especially during the child’s growth period. Particularly indicated for this type of pathology, Spineway’s patented Mont Blanc 3D+ implant makes it possible to correct the deformity while keeping the natural curves of the spine.”Present in Thailand since 2016 through exclusive distribution, Spineway continues to develop its know-how on the Asian continent with the implementation of a national distribution agreement within the main healthcare centers in Malaysia, a few months after the signing of an exclusive commercial agreement for the sale of its products in Japan1. Spineway and its partner will promote and introduce the whole product portfolio, in particular, the specific solutions for mini-invasive surgery Mont-Blanc MIS.Stéphane Le Roux, CEO of Spineway, says : “We are delighted with this partnership in Malaysia, a country recognized as having one of the best healthcare systems in Asia. Our Mont-Blanc MIS and MISTI platform designed by Spineway will address the market needs by providing advanced surgical techniques to surgeons and patients”.Sales are scheduled to start in June 2020, immediately after the product registration will be granted by the Medical Device Authority in Malaysia.This first implantation of the Mont Blanc 3D+ in Thailand and this new distribution agreement in Malaysia demonstrate that Spineway continues its development in Asia thanks to the high added value of its technologies. Upcoming: April 15th, 2021 – Publication of first quarter 2021 revenues
March 8th, 2021 – General meetingThe annual accounts and and the preparatory documents for the Shareholders’ Meeting
are available on the company’s website in the InvestorsSPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.comThis press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).
ISIN: FR0011398874 – ALSPWContacts:
1Press release of April 23, 2020
AttachmentSPW_CP_Malaisie_VD_UK

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.